166 related articles for article (PubMed ID: 11323158)
21. [The effects of tamoxifen on the female genital tract].
Mourits MJ; van der Zee AG; Willemse PH; Hollema H; de Vries EG
Ned Tijdschr Geneeskd; 2003 Nov; 147(47):2315-20. PubMed ID: 14669536
[TBL] [Abstract][Full Text] [Related]
22. Tamoxifen, raloxifene and the prevention of breast cancer.
Bentrem DJ; Craig Jordan V
Minerva Endocrinol; 2002 Jun; 27(2):127-39. PubMed ID: 11961504
[TBL] [Abstract][Full Text] [Related]
23. Committee Opinion No. 601: Tamoxifen and uterine cancer.
Obstet Gynecol; 2014 Jun; 123(6):1394-1397. PubMed ID: 24848920
[TBL] [Abstract][Full Text] [Related]
24. [Effects of raloxifene on other organs without bone: uterus].
Nozaki M
Clin Calcium; 2004 Oct; 14(10):55-60. PubMed ID: 15577132
[TBL] [Abstract][Full Text] [Related]
25. ACOG committee opinion. No. 336: Tamoxifen and uterine cancer.
American College of Obstetricians and Gynecologists Committee on Gynecologic Practice
Obstet Gynecol; 2006 Jun; 107(6):1475-8. PubMed ID: 16738185
[TBL] [Abstract][Full Text] [Related]
26. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
Endocrinology; 2001 Feb; 142(2):838-46. PubMed ID: 11159857
[TBL] [Abstract][Full Text] [Related]
27. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
Jordan VC; Brodie AM
Steroids; 2007 Jan; 72(1):7-25. PubMed ID: 17169390
[TBL] [Abstract][Full Text] [Related]
28. Selective estrogen receptor modulators: a new category of compounds to extend postmenopausal women's health.
Goldstein SR
Int J Fertil Womens Med; 1999; 44(5):221-6. PubMed ID: 10569450
[TBL] [Abstract][Full Text] [Related]
29. Tamoxifen and toremifene treatment of breast cancer and risk of subsequent endometrial cancer: a population-based case-control study.
Pukkala E; Kyyrönen P; Sankila R; Holli K
Int J Cancer; 2002 Jul; 100(3):337-41. PubMed ID: 12115550
[TBL] [Abstract][Full Text] [Related]
30. Breast cancer risk management.
Reeder JG; Vogel VG
Clin Breast Cancer; 2007 Dec; 7(11):833-40. PubMed ID: 18269772
[TBL] [Abstract][Full Text] [Related]
31. [Selective estrogen receptor modulators (SERMs) in the practice].
Nagykálnai T
Magy Onkol; 2002; 46(2):165-75. PubMed ID: 12202896
[TBL] [Abstract][Full Text] [Related]
32. Tamoxifen and secondary tumours. An update.
Wilking N; Isaksson E; von Schoultz E
Drug Saf; 1997 Feb; 16(2):104-17. PubMed ID: 9067122
[TBL] [Abstract][Full Text] [Related]
33. Overview of the main outcomes in breast-cancer prevention trials.
Cuzick J; Powles T; Veronesi U; Forbes J; Edwards R; Ashley S; Boyle P
Lancet; 2003 Jan; 361(9354):296-300. PubMed ID: 12559863
[TBL] [Abstract][Full Text] [Related]
34. Comparative tolerability of first-generation selective estrogen receptor modulators in breast cancer treatment and prevention.
Curtis MG
Drug Saf; 2001; 24(14):1039-53. PubMed ID: 11735660
[TBL] [Abstract][Full Text] [Related]
35. Raloxifene is associated with less side effects than tamoxifen in women with early breast cancer: a questionnaire study from one physician's practice.
Rohatgi N; Blau R; Lower EE
J Womens Health Gend Based Med; 2002 Apr; 11(3):291-301. PubMed ID: 11988138
[TBL] [Abstract][Full Text] [Related]
36. Status of antiestrogen breast cancer prevention trials.
Powles TJ
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):28-31. PubMed ID: 9556788
[TBL] [Abstract][Full Text] [Related]
37. Selective estrogen receptor modulators.
Haskell SG
South Med J; 2003 May; 96(5):469-76. PubMed ID: 12911186
[TBL] [Abstract][Full Text] [Related]
38. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
Liu X; Pisha E; Tonetti DA; Yao D; Li Y; Yao J; Burdette JE; Bolton JL
Chem Res Toxicol; 2003 Jul; 16(7):832-7. PubMed ID: 12870885
[TBL] [Abstract][Full Text] [Related]
39. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.
Chlebowski RT; Collyar DE; Somerfield MR; Pfister DG
J Clin Oncol; 1999 Jun; 17(6):1939-55. PubMed ID: 10561236
[TBL] [Abstract][Full Text] [Related]
40. Update on raloxifene to prevent endometrial-breast cancer.
Goldstein SR
Eur J Cancer; 2000 Sep; 36 Suppl 4():S54-6. PubMed ID: 11056320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
